Prostate Cancer | Norton Healthcare

Indication: Prostate Cancer

A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer

Sub-indication: Genitourinary Cancer

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Janssen Research & Development

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.